View Older Stories View More Recent Stories

Jan 27, 2023 06:59AM Bristol-Myers Squibb (BMY) Reports Positive CHMP Opinion for Once-Daily Sotyktu
Jan 27, 2023 06:59AM Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
Jan 26, 2023 07:00AM Bristol-Myers Squibb (BMY) Reports TRANSCEND CLL 004 Trial of Breyanzi Met Primary Endpoint
Jan 26, 2023 06:59AM Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocyt
Jan 3, 2023 07:05AM Bristol Myers Squibb to Present at J.P. Morgan’s 41st Annual Healthcare Conference
Jan 3, 2023 07:00AM Bristol-Myers Squibb (BMY) completes sale of Syracuse, New York manufacturing facility
Jan 3, 2023 06:59AM Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York
Dec 16, 2022 03:40AM Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers Squibb
Dec 15, 2022 06:59AM Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023
Dec 12, 2022 06:59AM Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio
Dec 8, 2022 04:16PM Bristol Myers Squibb Announces Dividend Increase
Nov 29, 2022 08:00AM Envisagenics Announces Research Collaboration with Bristol Myers Squibb
Nov 9, 2022 06:59AM Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Conference
Nov 2, 2022 06:59AM Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to be Presented at American Heart Association Scientific Sessions 2022
Oct 31, 2022 07:02AM Bristol-Myers Squibb (BMY) Announces Phase 3 COMMANDS Trial Met its Primary Endpoint
Oct 31, 2022 06:59AM Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial
Oct 27, 2022 08:32AM Bristol-Myers Squibb (BMY) Extends Multi-Year Deal with Obsidian Therapeutics
Oct 27, 2022 08:30AM Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb
Oct 26, 2022 03:36AM Bristol-Myers Squibb (BMY) Reports Q3 Revenue of $11.22B, EPS of $1.99
Oct 26, 2022 03:30AM Bristol-Myers Squibb (BMY) Reports New Zeposia Data Shows COVID-19 Outcomes and Preservation of Long-Term Cognitive Function from Separate Analyses in Patients with Relapsing Forms of Multiple Scleros
Oct 26, 2022 02:00AM New Zeposia (ozanimod) Data Highlight COVID-19 Outcomes and Preservation of Long-Term Cognitive Function from Separate Analyses in Patients with Relapsing Forms of Multiple Sclerosis
Oct 25, 2022 07:31PM Bristol Myers Squibb Reports Third Quarter Financial Results for 2022 
Oct 24, 2022 06:59AM Bristol-Myers Squibb (BMY) Reports New Data Showing Continuous Zeposia (ozanimod) Treatment Prevents Disease Relapse Over One Year in 86.1% of Patients Who Respond at the End of the Induction Period
Oct 24, 2022 06:59AM New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia (ozanimod) Treatment Prevents Disease Relapse Over One Year in 86.1% of Patients
Oct 21, 2022 06:59AM Bristol-Myers Squibb (BMY) Announces FDA Accepts sNDA for CAMZYOS in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduction Therapy
Oct 21, 2022 06:59AM U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for CAMZYOS® (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduct
Oct 19, 2022 04:30PM Bristol Myers Squibb Presents Data from CheckMate -76K Showing Opdivo (nivolumab) Reduced the Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Me
Oct 7, 2022 06:59AM Bristol Myers Squibb Announces Change to Earnings Conference Call Dial-In Information for Third Quarter 2022 Results Scheduled for October 26, 2022
Oct 4, 2022 08:03AM Exelixis (EXEL) Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb (BMY)
Oct 4, 2022 08:00AM Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STE
Sep 16, 2022 04:15PM Bristol-Myers Squibb (BMY) Granted EU Approval of Opdualag
Sep 16, 2022 04:15PM Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with T
Sep 15, 2022 06:59AM Bristol-Myers Squibb (BMY) Reports Adjuvant Treatment with Opdivo Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS) in Patients with Stage
Sep 15, 2022 06:59AM Bristol Myers Squibb Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS) in Patients wit
Sep 14, 2022 04:16PM Bristol Myers Squibb Announces Dividend
Sep 12, 2022 06:26AM Bristol-Myers Squibb (BMY) Announces FDA Approval for Sotyktu to Treat Moderate-to-Severe Plaque Psoriasis
Sep 12, 2022 05:27AM Bristol-Myers Squibb (BMY) Reports Strong New Sotyktu Data
Sep 10, 2022 02:30AM Bristol Myers Squibb Announces New Sotyktu™ (deucravacitinib) Long-Term Data Showing Clinical Efficacy Maintained for Up to Two Years with Continuous Treatment in Moderate-to-Severe Plaque Psoriasis
Sep 9, 2022 10:38PM   U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis
Sep 7, 2022 07:00AM Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research
Sep 7, 2022 06:59AM Bristol Myers Squibb to Report Results for Third Quarter 2022 on October 26, 2022
Sep 6, 2022 06:59AM Bristol Myers Squibb to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Sep 5, 2022 06:59AM Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer
Aug 31, 2022 06:59AM Bristol Myers Squibb to Participate in Citi’s 17th Annual BioPharma Conference
Aug 28, 2022 03:36AM Late-Breaking Results From Phase 2 AXIOMATIC-SSP Study of Milvexian, an Investigational Oral Factor XIa Inhibitor, Show Favorable Antithrombotic Profile in Combination With Dual Antiplatelet Therapy
Aug 17, 2022 08:32AM Bristol-Myers Squibb (BMY) Completes Acquisition of Turning Point Therapeutics (TPRX)
Aug 17, 2022 08:31AM Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio
Aug 16, 2022 06:59AM Bristol-Myers Squibb (BMY), Turning Point Therapeutics (TPRX) Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition
Aug 16, 2022 06:59AM Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Th
Aug 15, 2022 11:31AM Big Short's Burry Liquidates ~$200M in Long Stock Bets, Now Has Just One Stock
View More Recent Stories View Older Stories